Scarica l'app Stockscreener
0.339
4.95%
0.016
Dopo l'orario di chiusura:
.32
-0.019
-5.60%
Precedente Chiudi:
$0.323
Aprire:
$0.3253
Volume 24 ore:
1.21M
Relative Volume:
0.51
Capitalizzazione di mercato:
$2.99M
Reddito:
$749.50K
Utile/perdita netta:
$-29.60M
Rapporto P/E:
-0.000902
EPS:
-376.0263
Flusso di cassa netto:
$-22.09M
1 W Prestazione:
-8.01%
1M Prestazione:
-67.71%
6M Prestazione:
-99.58%
1 anno Prestazione:
-99.76%
Intervallo 1D:
$0.31
$0.349
Intervallo di 1 settimana:
$0.31
$0.3789
Portata 52W:
$0.31
$380.00
Aditxt Inc Stock (ADTX) Company Profile
Nome
Aditxt Inc
Settore
Industria
Telefono
909-488-0844
Indirizzo
737 N. FIFTH STREET, SUITE 200, RICHMOND
Confronta ADTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| ADTX | 0.339 | 2.99M | 749.50K | -29.60M | -22.09M | -376.03 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Aditxt Inc Borsa (ADTX) Ultime notizie
ADTX stock plunges to 52-week low of $0.32 amid market challenges - Investing.com
Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 - The Malaysian Reserve
Evofem Cuts Q3 Operating Loss 31%, Acquires SOLOSEC Rights Despite Sales Dip | ADTX Stock News - StockTitan
Enviri Corp (NYSE: NVRI): Blank Check On Growth? - Stocks Register
Appili Therapeutics shareholders vote in favor of Aditxt transaction - TipRanks
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025 - The Manila Times
Aditxt, Inc. (NASDAQ:ADTX) Short Interest Update - Defense World
Aditxt suspends equity financing amid acquisition strategy - Investing.com
Aditxt suspends equity financing amid acquisition strategy By Investing.com - Investing.com UK
ADTX stock plunges to 52-week low, touches $0.42 - Investing.com India
ADTX stock plunges to 52-week low, touches $0.42 By Investing.com - Investing.com UK
Aditxt Secures Overwhelming Shareholder Approval for Appili Therapeutics Acquisition | ADTX Stock News - StockTitan
Appili Shareholders Approve Acquisition by Aditxt - TipRanks
Appili Therapeutics Announces Results of Special Meeting of Shareholders - Financial Post
Appili Therapeutics Announces Results of Special Meeting of Shareholders - GlobeNewswire Inc.
Aditxt announces Evofem secures voting agreements with investors for merger - TipRanks
Evofem Biosciences Gains Support for Aditxt Merger - TipRanks
Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem - Quantisnow
Evofem Secures Investor Support for Proposed Merger through Voting Agreements - StreetInsider.com
Evofem Secures Key Merger Support as Aditxt Completes $5M Investment Commitment | ADTX Stock News - StockTitan
Aditxt Discloses Information About Compliance with Nasdaq Listing Requirements in 8-K Filing** - Defense World
Aditxt, Inc. Focuses on Growth Amid Nasdaq Compliance - TipRanks
A Biotech Empire Rises in Inland Southern California - Site Selection Magazine
Aditxt receives positive FDA feedback on ATI-1801 development By Investing.com - Investing.com Australia
ADTXAditxt, Inc. Latest Stock News & Market Updates - StockTitan
Aditxt receives positive FDA feedback on ATI-1801 development - Investing.com India
Evofem Biosciences enters agreements amid merger plans - Investing.com
Evofem Biosciences Faces Merger and Credit Challenges - TipRanks
Evofem Biosciences enters agreements amid merger plans By Investing.com - Investing.com UK
ADTX stock plunges to 52-week low of $0.53 amid market challenges - Investing.com
Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission - StockTitan
Appili Therapeutics’ FDA Alignment and Aditxt Acquisition - TipRanks
Appili Therapeutics announces FDA alignment on ATI-1801 NDA requirements - TipRanks
Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission - The Manila Times
Aditxt Enters Major Investment Agreement with Evofem - TipRanks
Aditxt appoints Sylvia Hermina to board By Investing.com - Investing.com Canada
Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives - Quantisnow
Aditxt appoints Sylvia Hermina to board - Investing.com
Aditxt, Inc. Appoints Sylvia Hermina to its Board of Directors - Marketscreener.com
Evofem Biosciences, Inc. announced that it has received $2.28 million in funding from Aditxt, Inc. - Marketscreener.com
Is Aditxt Inc (NASDAQ: ADTX) Doomed From The Get-Go? - Stocks Register
Evofem Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - Quantisnow
Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem - Quantisnow
ADTX stock touches 52-week low at $0.89 amid sharp decline - Investing.com UK
Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time - StockTitan
Aditxt shares sold by major stakeholder HRT Financial for $29,874 - Investing.com South Africa
ADTX stock touches 52-week low at $1.07 amid steep annual decline - Investing.com
ADTX stock touches 52-week low at $1.07 amid steep annual decline By Investing.com - Investing.com South Africa
Why Aditxt Inc Stock Might Make Sense If Bought Today - Stocks Register
There is no way Aditxt Inc (ADTX) can keep these numbers up - SETE News
Aditxt Inc (ADTX) requires closer examination - US Post News
Aditxt Inc Azioni (ADTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):